Elocom

Elocom is a prescription topical medication that contains the corticosteroid mometasone furoate as its active ingredient. It is formulated for skin application and marketed in the European Union. The product is classified as a potent topical corticosteroid and is used under medical supervision to manage inflammatory skin conditions such as eczema and psoriasis. Elocom is supplied as a cream or ointment for uniform distribution across the affected area.

Elocom is indicated for the topical treatment of various inflammatory and pruritic skin disorders, and it may be prescribed when a medium‑to high‑potency corticosteroid is appropriate.

- Mild to moderate atopic dermatitis (eczema) affecting limited skin areas. - Plaque psoriasis lesions where a potent corticosteroid is required. - Seborrheic dermatitis of the scalp, face, or torso. - Allergic contact dermatitis caused by irritants or allergens. - Discontinuous or localized rash such as nummular eczema. - Pruritic dermatoses like lichen simplex chronicus resistant to milder steroids. - Localized inflammatory lesions of lupus erythematosus (discoid type) when other therapies are insufficient.

Topical application of Elocom may cause local skin reactions, most of which are mild and reversible.

Common: - Transient burning or stinging at the application site, usually brief. - Mild itching or dryness, often relieved with moisturizers. - Erythema or mild redness localized to the treated area. - Folliculitis or acne‑like eruption around hair follicles.

Serious: - Skin atrophy or thinning with prolonged use, increasing injury risk. - Development of striae (stretch marks), especially in flexural areas. - Hypersensitivity reactions such as contact dermatitis, with intense itching and swelling. - Rare systemic adrenal suppression, presenting as fatigue or low blood pressure.

When using Elocom, several precautions should be observed to minimize risks and ensure safe therapy.

- Apply only to intact skin; avoid broken or infected areas. - Limit use to the prescribed body surface area and duration. - Do not use on the face, groin, or underarms unless directed. - Avoid occlusive dressings unless specifically recommended. - Discontinue if signs of skin thinning, striae, or severe irritation develop. - Use with caution in patients with diabetes, hypertension, or immune suppression. - Pregnancy and breastfeeding considerations should be discussed with a healthcare provider.

Elocom may interact with other topical or systemic agents; awareness of potential interactions helps prevent adverse effects.

Avoid: - Concurrent use with other potent topical corticosteroids on the same area. - Application over large surface areas combined with systemic steroids. - Use on compromised skin together with abrasive agents (e.g., scrubs).

Use with caution: - Use with topical calcineurin inhibitors; monitor for additive immunosuppression. - Co‑administration with antiviral or antifungal creams; assess for reduced efficacy. - Patients on CYP3A4 inhibitors; observe for increased systemic absorption. - Concurrent systemic immunosuppressants (e.g., methotrexate); monitor for enhanced immunosuppression.

Interactions can affect drug absorption, potency, or increase the risk of systemic side effects.